Rationally Designed Oral DOX Gels for Colon-Specific Administration

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Oncology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer-related mortality.
• Conventional CRC treatments face challenges with systemic side effects due to non-specific drug distribution.
• Targeted oral drug delivery aims to enhance therapeutic efficacy and minimize adverse effects by delivering agents directly to the colon.

Purpose of the Study:

• To design and evaluate a novel oral drug delivery system for targeted colon cancer therapy.
• To overcome the challenge of premature drug release and degradation in the upper gastrointestinal tract.
• To assess the efficacy of the developed system in delivering doxorubicin (DOX) to the colon.

Main Methods:

• Development of pectin-chalk-doxorubicin (PC-DOX) gels using biocompatible chalk and pectin cross-linked with calcium ions.
• In vitro assessment of drug leakage in simulated gastric acid.
• Evaluation of colon delivery efficiency and drug uptake by colon cancer cells in simulated colon environments.
• In vivo studies in mice to determine colonic delivery efficiency.

Main Results:

• The PC-DOX gels demonstrated dual protection, significantly reducing drug leakage in gastric acid.
• In vitro studies achieved a 68% colon delivery efficiency.
• The released chalk did not impede doxorubicin uptake by colon cancer cells.
• In vivo experiments confirmed the highest colonic delivery efficiency with the rationally designed PC-DOX system.

Conclusions:

• The developed PC-DOX gel system offers a promising strategy for targeted oral delivery of chemotherapy agents to the colon.
• This approach has significant potential for improving the treatment of colon cancer by enhancing drug efficacy and reducing side effects.
• The dual protection mechanism and biocompatibility of the materials contribute to the system's effectiveness.